March 25, 2026 a 11:43 am
BDX: Fundamental Ratio Analysis - Becton, Dickinson and Company
Becton, Dickinson and Company stands at the forefront of medical supply innovation. With an extensive product range and a strong industry presence, BDX is strategically positioned in the medical instruments and supplies sector. This analysis will dive into the recent performance and future outlook for the company.
Fundamental Rating
Becton, Dickinson and Company demonstrates a solid performance with room for improvement in certain areas.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 3 | |
| Return on Assets | 4 | |
| Debt to Equity | 1 | |
| Price to Earnings | 2 | |
| Price to Book | 3 |
Historical Rating
The latest scores reflect a stable performance compared to previous assessments.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-03-24 | 3 | 5 | 3 | 4 | 1 | 2 | 3 |
| 2026-03-23 | - | 5 | 3 | 4 | 1 | 2 | 3 |
Analyst Price Targets
Expectations are set high, with a potential target growth range.
| High | Low | Median | Consensus |
|---|---|---|---|
| $215 | $170 | $202 | $193.8 |
Analyst Sentiment
The sentiment among analysts leans towards a recommendation to buy.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 16 | |
| Hold | 16 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
Becton, Dickinson and Company presents a strong investment case with solid fundamentals in the medical supplies sector. The company has a diversified product portfolio which ensures stability in fluctuating markets. However, the current debt-to-equity ratio suggests cautious optimism. Analysts show a balanced sentiment with a lean towards buy recommendations, and competitive price targets indicate room for value appreciation. Potential investors should weigh these factors against broader market conditions and individual financial goals.